Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 228

1.

Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.

Lin E, Wexler TL, Nachtigall L, Tritos N, Swearingen B, Hemphill L, Loeffler J, Biller BM, Klibanski A, Miller KK.

Clin Endocrinol (Oxf). 2012 Sep;77(3):430-8. doi: 10.1111/j.1365-2265.2012.04361.x.

2.

Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.

Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C, Hemphill L, Nachtigall L, Loeffler J, Swearingen B, Biller BM, Klibanski A.

J Clin Endocrinol Metab. 2010 Feb;95(2):567-77. doi: 10.1210/jc.2009-1611. Epub 2010 Jan 8.

3.

Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents.

Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R.

J Clin Endocrinol Metab. 2001 Mar;86(3):1061-5.

PMID:
11238486
4.

Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Beauregard C, Utz AL, Schaub AE, Nachtigall L, Biller BM, Miller KK, Klibanski A.

J Clin Endocrinol Metab. 2008 Jun;93(6):2063-71. doi: 10.1210/jc.2007-2371. Epub 2008 Apr 1.

6.

The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.

Deepak D, Daousi C, Javadpour M, Clark D, Perry Y, Pinkney J, Macfarlane IA.

Growth Horm IGF Res. 2010 Jun;20(3):220-5. doi: 10.1016/j.ghir.2010.02.002. Epub 2010 Feb 24.

PMID:
20185347
7.

Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women.

Utz AL, Yamamoto A, Hemphill L, Miller KK.

J Clin Endocrinol Metab. 2008 Jul;93(7):2507-14. doi: 10.1210/jc.2008-0169. Epub 2008 Apr 29.

8.

Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.

Wexler TL, Durst R, McCarty D, Picard MH, Gunnell L, Omer Z, Fazeli P, Miller KK, Klibanski A.

Growth Horm IGF Res. 2010 Oct;20(5):333-7. doi: 10.1016/j.ghir.2010.05.003. Epub 2010 Jul 3.

9.

GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency.

Giavoli C, Profka E, Verrua E, Ronchi CL, Ferrante E, Bergamaschi S, Sala E, Malchiodi E, Lania AG, Arosio M, Ambrosi B, Spada A, Beck-Peccoz P.

J Clin Endocrinol Metab. 2012 Nov;97(11):3983-8. doi: 10.1210/jc.2012-2477. Epub 2012 Aug 17.

PMID:
22904173
10.

Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.

Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A.

J Clin Endocrinol Metab. 2002 Apr;87(4):1692-9.

PMID:
11932303
11.

Elderly people with hypothalamic-pituitary disease and growth hormone deficiency: lipid profiles, body composition and quality of life compared with control subjects.

Li Voon Chong JS, Benbow S, Foy P, Wallymahmed ME, Wile D, MacFarlane IA.

Clin Endocrinol (Oxf). 2000 Nov;53(5):551-9.

PMID:
11106915
12.

Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency.

Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T.

J Clin Endocrinol Metab. 1998 Oct;83(10):3476-9.

PMID:
9768649
13.

Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly.

Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA.

Endocr Pract. 2007 Jul-Aug;13(4):363-72.

PMID:
17669712
14.
15.

Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity.

Makimura H, Stanley T, Mun D, Chen C, Wei J, Connelly JM, Hemphill LC, Grinspoon SK.

J Clin Endocrinol Metab. 2009 Dec;94(12):5131-8. doi: 10.1210/jc.2009-1295. Epub 2009 Oct 16.

16.

Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly.

Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G.

Clin Endocrinol (Oxf). 2001 Apr;54(4):515-24.

PMID:
11318788
17.

Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity.

Bredella MA, Gerweck AV, Lin E, Landa MG, Torriani M, Schoenfeld DA, Hemphill LC, Miller KK.

J Clin Endocrinol Metab. 2013 Sep;98(9):3864-72. doi: 10.1210/jc.2013-2063. Epub 2013 Jul 3.

18.

Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.

Bredella MA, Lin E, Brick DJ, Gerweck AV, Harrington LM, Torriani M, Thomas BJ, Schoenfeld DA, Breggia A, Rosen CJ, Hemphill LC, Wu Z, Rifai N, Utz AL, Miller KK.

Eur J Endocrinol. 2012 Apr;166(4):601-11. doi: 10.1530/EJE-11-1068. Epub 2012 Jan 24.

19.

Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.

Pekic S, Doknic M, Miljic D, Joksimovic M, Glodic J, Djurovic M, Dieguez C, Casanueva F, Popovic V.

Eur J Endocrinol. 2006 May;154(5):659-66.

20.

IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Reid TJ, Jin Z, Shen W, Reyes-Vidal CM, Fernandez JC, Bruce JN, Kostadinov J, Post KD, Freda PU.

Pituitary. 2015 Dec;18(6):808-19. doi: 10.1007/s11102-015-0657-2.

Supplemental Content

Support Center